---
title: "Lysergide (DT120) in Generalized anxiety disorder: Incidence"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Incidence. Topics: United States diagnosed incidence: Komodo Healthcare Map claims, adults, 2020 to 2023; United States first incidence of DSM-IV generalized anxiety disorder: NESARC Waves 1 and 2; Predictors of incident generalized anxiety disorder: NESARC; Age at onset: NCS-R and NCS-A, United States; 3 further topics. 7 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/incidence"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Incidence

<a id="heading-2.2.1.2.1"></a>

## 2.2.1.2.1 Incidence of Generalized anxiety disorder

<a id="topic-2.2.1.2.1-1"></a>

### United States diagnosed incidence: Komodo Healthcare Map claims, adults, 2020 to 2023

> “We estimated the prevalence and incidence of diagnosed GAD among adults in the U.S. healthcare system using payer-complete closed claims data from the Komodo Healthcare Map™ database from January 1, 2020 to December 31, 2023. Patients with GAD were identified using ICD-10 code F41.1.”
> “The numerator consisted of patients with a new GAD diagnosis in the index year and no documented GAD diagnosis during the prior two calendar years.”
> “The annual incidence of GAD in the U.S. among adults engaging with the healthcare system ranged from 2.1% to 2.3%, using a 2-year pre-index lookback to confirm no prior diagnosis and identify newly diagnosed cases”
> “Claims data represent treatment-seeking patients, which may limit generalizability to a broader population.”

Source: [Ferries et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13019603/)

<a id="topic-2.2.1.2.1-2"></a>

### United States first incidence of DSM-IV generalized anxiety disorder: NESARC Waves 1 and 2

> “One-year incidence rates of DSM-IV substance, mood and anxiety disorders were highest for alcohol abuse (1.02) alcohol dependence (1.70), major depressive disorder (MDD: 1.51) and generalized anxiety disorder (GAD: 1.12).”
> “The 1-year incidence rates and 1-year incidence rates per 100 py were very similar given the small numbers of incident cases (Table 1), and are reported hereinafter as rates per 100 py at risk.”
> “Only the Netherlands survey reported incidence of DSM-III-R specific phobia (2.20) and generalized anxiety disorder (GAD) (0.72).”

Source: [Grant et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2766434/)

<a id="topic-2.2.1.2.1-3"></a>

### Predictors of incident generalized anxiety disorder: NESARC

> “Women were at increased risk of all incident anxiety disorders except social phobia (Table 4). Risks of incident panic disorder and social phobia were greater among respondents 20-to-54 years-old, whereas increased risks of specific phobia and GAD were only observed among 30-to-54 year-olds. Except for specific phobia, the risks of incident anxiety disorders were increased among respondents with incomes ≤ $19,999/year. The risk of incident GAD was also greater among respondents who were separated/divorced/widowed and lower among Hispanics.”
> “Increased risk of incident GAD was observed among respondents with baseline MDD, bipolar I, panic disorder, and social phobia, and with schizotypal, borderline, and narcissistic PDs.”
> “One of the most interesting findings of this study was the reciprocal temporal relationships between MDD and GAD, and GAD and panic disorder.”

Source: [Grant et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2766434/)

<a id="topic-2.2.1.2.1-4"></a>

### Age at onset: NCS-R and NCS-A, United States

> “First, median AOO (i.e. the 50th percentile on the AOO curves) is earliest for the phobias and SAD (ages 15–17) and latest for PD (age 23), MDE (age 25), and GAD (age 30).”
> “MDE, GAD, and PD, at the other extreme, have IQRs in the range 23–27 years.”
> “Indeed, a comparison of cumulative lifetime prevalence estimates as of age 64 with those as of age 17 in Figures 2 and 3 shows that an estimated 69–74% of all lifetime cases of MDE, GAD, and PD have first onsets in the age range 18–64.”

Source: [Kessler et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4005415/)

<a id="topic-2.2.1.2.1-5"></a>

### Age at onset: meta-analysis of 192 epidemiological studies

| Measure | Generalised anxiety disorder |
| --- | --- |
| No of samples | “24” |
| Peak age at onset (years) | “15.5” |
| Proportion onset by 14 years | “8.6%” |
| Proportion onset by 18 years | “20.4%” |
| Proportion onset by 25 years | “33.0%” |
| 25th percentile age at onset (years) | “20” |
| Median age at onset (years) | “32” |
| 75th percentile age at onset (years) | “42” |

Source: [Solmi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8960395/)

<a id="topic-2.2.1.2.1-6"></a>

### Global incidence of anxiety disorders (all types combined): Global Burden of Disease Study 2019

> “Globally, the estimated newly-diagnosed anxiety disorders patients increased from 31.13 (95% UI: 25.08, 37.92) million in 1990 to 45.82 (95% UI: 37.14, 55.62) million in 2019, with a relatively stable ASIR of about 5.8 (95% UI: 4.68, 7.03) cases per 1000 population over the past 30 years”
> “The incidence rate of anxiety disorders rose to a peak at age 10–14 years, remained relatively high level until age 40–44 years, and dropped substantially afterward among both sexes in 2019”

Source: [Yang et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8157816/)

<a id="topic-2.2.1.2.1-7"></a>

### High-income North America incidence of anxiety disorders (all types combined): Global Burden of Disease Study 2019

| Region | Incident cases in 2019, millions (95% UI) | Age-standardised incidence rate per 1000 in 2019 (95% UI) |
| --- | --- | --- |
| High-income North America | “2.86 (2.31, 3.52)” | “8.06 (6.44, 9.87)” |

Source: [Yang et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8157816/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
